This site is for Canadian Healthcare Professionals.
This site is for Canadian Healthcare Professionals.

The COVID-19 virus has evolved. Are you helping patients stay more protected for Fall 2024?

Stay up to date with the latest SPIKEVAX information in our quick reference DASH (dosage, administration, storage and handling) guide for health care providers.

SPIKEVAX DASH document
Share this site

24 hour post-puncture stability

SPIKEVAX is preservative free. Once the vial has been entered (punctured), it should be discarded after 24 hours if refrigerated post-puncture or after 12 hours if stored at room temperature post-puncture.

Storage after thawing

Unpunctured Vial (Prior to first use)Punctured Vial (After first dose has been withdrawn)
Refrigerate at 2° to 8°C for up to 50 days. Cool storage up to room temperature 8° to 25°C for 12 hours
Refrigerate at 2° to 8°C for up to 24 hours. Cool storage up to room temperature 8° to 25°C for 12 hours
Never refreeze thawed vaccines!

Administration for multi-dose vial

Prior to injection, inspect each dose to:

1

Confirm liquid is white to off-white

Confirm liquid is white to off-white in colour in both vial and syringe.

  • SPIKEVAX may contain white or translucent product-related particulates.
  • Do not administer the vaccine if it is discoloured or contains other particulate matter.
  • For detailed information regarding storage and handling, see the Product Monograph.
2

Verify syringe volume

Verify syringe volume based on recommended dose and dose volume (refer to the dosing information above).

  • If the amount of SPIKEVAX remaining in the vial cannot provide a full dose, discard the vial and contents. Do not pool excess SPIKEVAX from multiple vials.
  • Pierce the stopper preferably at a different site each time.
  • Discard vial 24 hours after first puncture, even if vaccine remains in the vial.
3

Administer SPIKEVAX

Administer SPIKEVAX by intramuscular (IM) injection only

  • The preferred site is the deltoid muscle of the upper arm or, in infants and young children, the anterolateral aspect of the thigh.
  • A needle length of ≥1 inch should be used as needles <1 inch may be of insufficient length to penetrate muscle tissue in some adults.

Blue cap

SPIKEVAX
andusomeran
0.1 mg/mL
Multidose vial 2.5 mL

For illustrative purpose only.


Storage after first dose has been withdrawn

Thawed vials can be handled in room light conditions.

  • Once the vial has been entered, discard vial after 24 hours if refrigerated between 2° to 8°C (36° to 46°F) and discard vial after 12 hours if stored at room temperature.
  • Record the date and time of first use on the vial label.
  • Once the vial has been punctured to withdraw the initial dose, the vaccine should be used immediately.
  • Any unused vaccine or waste material should be disposed of in accordance with local requirements.
  • NEVER refreeze thawed vaccine
Indication and clinical use

SPIKEVAX (COVID-19 mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

Pediatrics: Safety and efficacy in individuals <6 months of age not established.

Contraindications:

  • Hypersensitivity to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container.

Relevant warnings and precautions:

  • Hypersensitivity and anaphylaxis
  • Myocarditis and pericarditis
  • Patients with acute infection
  • Patients with hematologic disorders or on anticoagulant therapy
  • Patients who are immunocompromised
  • Syncope
  • Vaccination with SPIKEVAX may not protect all recipients

For more information:
Please consult the Product Monograph at spikevaxpro.com/pm for important information relating to adverse reactions, drug interactions, and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling us at 1-866-MODERNA (1-866-663-3762).

Stay up to date

Receive the latest information about mRESVIA and all the products in the Moderna pipeline.

By submitting your information, you agree to Moderna's Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna's Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


About Moderna
Company
Connect with Us
Report a side effect:
Adverse Event Intake Portal
Terms and conditionsPrivacy statement

© 2024 ModernaTX, Inc. CA-COV-2300031 09/2024